Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Summary
Lantern Pharma announced the commercial launch of withZeta.ai, a multi-agentic AI co-scientist platform for rare and complex cancer drug development, and repositioned predictBBB.ai into a broader molecular intelligence web service. The company reported Q1 2026 results showing a 47% reduction in R&D spend year-over-year, a 27% reduction in net loss, and pro forma liquidity bolstered by a recent financing expected to extend runway into Q1 2027. Lantern received favorable regulatory outcomes, including an FDA Type C meeting result for the LP-300 HARMONIC™ trial and IND clearance for a pediatric CNS trial through subsidiary Starlight Therapeutics. The company outlined plans to separate withZeta.ai into an independent business entity to attract dedicated funding and commercialize its AI platform through subscriptions and partnerships.
Classifications
AskAI Classifications
LabelsLinked Companies
